Calcium-Activated Switch Enhances Antibody-Drug Conjugate Delivery and Potency in Cancer Treatment
核心洞察
Researchers at KTH Royal Institute of Technology (搜索) developed a calcium-activated delivery system that improves antibody-drug conjugate penetration into cancer (搜索) cells by exploiting calcium concentration differences.
The calcium-regulated affinity (CaRA) system binds strongly to EGFR (搜索) receptors in high-calcium environments outside cells, then releases inside cells where calcium levels are lower.
Testing with mertansine DM1 (搜索) payload showed extremely low concentrations needed to kill 50% of high EGFR (搜索)-expressing cancer (搜索) cells, with no effect on low EGFR-expressing healthy cells.
Researchers have developed a novel calcium-activated delivery system that significantly improves the effectiveness of antibody-drug conjugates (搜索) (ADCs) in cancer (搜索) treatment. The breakthrough, led by Professor Sophia Hober at KTH Royal Institute of Technology (搜索) in collaboration with Stanford University and Umeå University, addresses a critical challenge in targeted cancer therapy where drugs often fail to penetrate deep enough into tumor cells to deliver their lethal payload.
Overcoming ADC Delivery Limitations
The research team tackled a fundamental problem with current targeted cancer (搜索) drugs: they tend to bind too tightly to tumor cell receptors, becoming stuck at the cell surface without reaching their intended destination—the lysosome, an acidic compartment where the targeting protein can be broken down to release cell-killing toxins.
"The calcium switch is built into the drug design," explains Hober. "It senses calcium levels and changes its grip automatically."
Calcium-Regulated Affinity Technology
The innovative solution exploits the natural calcium concentration gradient between the extracellular environment and the inside of cells. The calcium-regulated affinity (CaRA) system binds strongly to epidermal growth factor receptor (搜索) (EGFR (搜索)) on the outside of cancer (搜索) cells, where relatively high calcium concentrations are found in blood and extracellular fluid.
Once the drug-loaded protein and EGFR (搜索) are bound together, they are pulled inside the cell into compartments with gradually lower calcium levels. Because their bond is calcium-dependent, the receptor and CaRA eventually separate: the receptor can recycle back to the cell membrane, while CaRA continues carrying its payload toward the lysosome for targeted cell destruction.
Promising Preclinical Results
The study, published in PNAS (Proceedings of the National Academy of Sciences), demonstrated the system's effectiveness using living human cancer (搜索) cell lines with mertansine DM1 (搜索) as the cytotoxic payload. Co-authors Malin Jönsson and Marit Möller, both postdoctoral researchers at KTH, reported that the concentration of the CaRA EGFR (搜索)–DM1 conjugate needed to kill 50 percent of high EGFR-expressing cancer cells was extremely low, indicating very high potency.
Critically, the drug conjugate showed remarkable selectivity. "The drug conjugate is highly selective—it only kills cells that overexpress EGFR (搜索), leaving healthy or low-EGFR cells unharmed," Jönsson notes. "This shows specific targeting and a strong therapeutic window, which is critical for reducing side effects."
Clinical Implications
The calcium-activated delivery system represents a significant advancement in precision oncology, potentially enabling more effective cancer (搜索) treatment with lower drug doses and reduced collateral damage to healthy tissue. By solving the delivery problem that has limited the effectiveness of many ADCs, this technology could improve therapeutic outcomes while minimizing the severe side effects often associated with cancer treatments.
The research demonstrates how exploiting fundamental cellular biology—in this case, calcium concentration gradients—can lead to innovative solutions for drug delivery challenges that have long plagued the field of targeted cancer (搜索) therapy.